GT Biopharma, Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
On September 2, 2026, GT Biopharma's Board eliminated all outstanding Series A through K Preferred Stock (11 series total) via Certificates of Elimination filed with Delaware. Simultaneously, the company executed a 25-to-1 reverse stock split of Common Stock, reducing authorized Common shares from 625M to 25M post-split, while authorized Preferred shares were set at 1.5M. No dollar amounts, share counts, or preferred holder information disclosed. Effective date: September 8, 2026.
Why this rating
Reverse split + preferred elimination are significant capital-structure changes for micro-cap ($8.6M). Suggests addressing overhang/dead securities or preparing for financing. Lacks specifics on motivation or dilution impact; appears moderately material but not transformational.
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.